IPSENACT AKTIE | Aktienkurs | Nachrichten | Kurs

DAX	6.340	0,4%	Dow	12.455	-0,6%	Euro	1,2519	-0,2%
ESt50	2.162	0,3%	Nas	2.838	-0,1%	Öl	106,9	0,1%
TDax	752,5	0,1%	Nikkei	8.580	0,2%	Gold	1.573	0,9%

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Depot
Times + Sales	Chart-Analyse	Analysen	Dividende/HV	Profil	Optionsscheine	Watchlist
Börsenplätze	Chartvergleich	Kursziele		Insidertrades	Knock-outs	myHome
Orderbuch	Realtime Stuttgart	RSS Feed	Analyse	im Forum	Fonds	Senden/Drucken
Historisch	Realtime Push	myNews neu		IR-Daten	Anleihen	handeln

Relevant
Alle
vom Unternehmen

Sprache:
Alle
DE
EN

Sortieren:
Datum
meistgelesen

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

21.05.12	600 Patients Recruited in Active Biotech?s and Ipsen?s tasquinimod Clinical Phase III Study (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
04.05.12	Ipsen: Combined Shareholders? Meeting of June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders? Meeting to be held on June 1, 2012 (Businesswire)
25.04.12	Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ) (Businesswire)
17.04.12	Ipsen?s Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B (Businesswire)

21.05.12	600 Patients Recruited in Active Biotech?s and Ipsen?s tasquinimod Clinical Phase III Study (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
04.05.12	Ipsen: Combined Shareholders? Meeting of June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders? Meeting to be held on June 1, 2012 (Businesswire)
25.04.12	Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ) (Businesswire)
17.04.12	Ipsen?s Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B (Businesswire)

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

21.05.12	600 Patients Recruited in Active Biotech?s and Ipsen?s tasquinimod Clinical Phase III Study (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
04.05.12	Ipsen: Combined Shareholders? Meeting of June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders? Meeting to be held on June 1, 2012 (Businesswire)
25.04.12	Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ) (Businesswire)
17.04.12	Ipsen?s Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B (Businesswire)

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

21.05.12	600 Patients Recruited in Active Biotech?s and Ipsen?s tasquinimod Clinical Phase III Study (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
04.05.12	Ipsen: Combined Shareholders? Meeting of June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders? Meeting to be held on June 1, 2012 (Businesswire)
25.04.12	Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ) (Businesswire)
17.04.12	Ipsen?s Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

21.05.12	600 Patients Recruited in Active Biotech?s and Ipsen?s tasquinimod Clinical Phase III Study (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders? Meeting to be held on June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
04.05.12	Ipsen: Combined Shareholders? Meeting of June 1, 2012 (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

21.05.12	600 Patients Recruited in Active Biotech?s and Ipsen?s tasquinimod Clinical Phase III Study (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders? Meeting to be held on June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
04.05.12	Ipsen: Combined Shareholders? Meeting of June 1, 2012 (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)

21.05.12	600 Patients Recruited in Active Biotech?s and Ipsen?s tasquinimod Clinical Phase III Study (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders? Meeting to be held on June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
04.05.12	Ipsen: Combined Shareholders? Meeting of June 1, 2012 (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)

Keine Nachrichten im Zeitraum eines Monats in dieser Kategorie verfügbar

21.05.12	600 Patients Recruited in Active Biotech?s and Ipsen?s tasquinimod Clinical Phase III Study (Businesswire)
26.04.12	Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders? Meeting to be held on June 1, 2012 (Businesswire)
03.05.12	Ipsen's First Quarter 2012 Sales (Businesswire)
18.05.12	Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting (Businesswire)
04.05.12	Ipsen: Combined Shareholders? Meeting of June 1, 2012 (Businesswire)
09.05.12	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen
Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen
vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

IpsenAct zu myNews hinzufügen Was ist das?

Kurszeit	09:01:06	Kursdatum	25.05.2012
Tageshoch	20,29	Eröffnung	20,29
Tagestief	20,29	Vortag	20,32
52 W. Hoch	28,63	Volumen (Stück)	n/a
52 W. Tief	19,21	Marktkapitalisierung (EUR)	1,75 Mrd.
52 W. Performance		Börse	FSE

Kurszeit	17:35:00	Kursdatum	25.05.2012
Tageshoch	20,85	Eröffnung	20,40
Tagestief	20,40	Vortag	20,74
52 W. Hoch	28,75	Volumen (Stück)	50.398
52 W. Tief	18,26	Marktkapitalisierung (EUR)	1,75 Mrd.
52 W. Performance		Börse	PAR

04.05.12	IpsenAct hold	Société Générale Group S.A. (SG)
01.03.12	IpsenAct underperform	Credit Suisse Group
01.03.12	IpsenAct hold	Société Générale Group S.A. (SG)
30.01.12	IpsenAct buy	Société Générale Group S.A. (SG)
25.10.11	IpsenAct buy	Société Générale Group S.A. (SG)

30.01.12	IpsenAct buy	Société Générale Group S.A. (SG)
25.10.11	IpsenAct buy	Société Générale Group S.A. (SG)
03.10.11	IpsenAct buy	Société Générale Group S.A. (SG)
31.08.11	IpsenAct buy	Société Générale Group S.A. (SG)
25.08.11	IpsenAct buy	Société Générale Group S.A. (SG)

04.05.12	IpsenAct hold	Société Générale Group S.A. (SG)
01.03.12	IpsenAct hold	Société Générale Group S.A. (SG)
06.05.10	Ipsen "equal weight"	Barclays Capital
28.10.09	Ipsen hold	Société Générale Group S.A. (SG)
20.10.09	Ipsen hold	Société Générale Group S.A. (SG)

Finanzen.net

IpsenAct Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Realtimekurs IpsenAct in Euro

Aktienkurs IpsenAct in EUR

Aktienkurs IpsenAct in EUR

Nachrichten zu IpsenAct

Analysen zu IpsenAct

IpsenAct CHART - 1 Jahr - FSE

ANZEIGE

Rating für IpsenAct:

Kursziele für IpsenAct

IpsenAct Kennzahlen

IpsenAct Historische Kurse

Zur Aktie IpsenAct

Zum Unternehmen IpsenAct

Aktien gleicher Branche mit besserer 1J Perf.

Passende Fonds

Marktkapitalisierung in Mrd. EUR	1,75
Anzahl Aktien in Mio.	84,25

25.05.2012	20,29
24.05.2012	20,32
23.05.2012	20,47
22.05.2012	20,37
21.05.2012	20,22

Mania Technologie	+456,3%
emQtec	+375,0%
CPU Softwarehouse	+363,3%
Windhoff	+354,5%
Stolberger Telecom	+350,0%

01.03.12	IpsenAct underperform	Credit Suisse Group
10.10.11	IpsenAct sell	Citigroup Corp.
30.08.11	IpsenAct sell	Citigroup Corp.

WKN	A0ESMG
ISIN	FR0010259150